Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

References

• Tay J, Vij R, Norkin M, et al. Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. Leuk Lymph. 2019;60(5):1275–1282.
   PubMed Web of Science ®Google Scholar
• Despiégel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19(1):e13–e28.
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Burns D, Baio G, et al. Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. Health Econ. 2019;28(5):653–665.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431–e442.
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32(25):2712–2717.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Baljevic M, et al. Multiple myeloma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 2020. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. [cited 2019 Dec 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Hamilton BK, Hashmi SK, et al. Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2018;24(8):1546–1553.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670–1678.
   PubMed Web of Science ®Google Scholar
• Stead ML, Brown JM, Velikova G, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999;104(3):605–611.
   PubMed Web of Science ®Google Scholar
• Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019;107:153–163.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–144.
   PubMed Web of Science ®Google Scholar
• Musoro JZ, Bottomley A, Coens C, et al. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. Eur J Cancer. 2018;104:169–181.
   PubMed Web of Science ®Google Scholar
• Royle KL, Gregory WM, Cairns DA, et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br J Haematol. 2018;182(6):816–829.
   PubMed Web of Science ®Google Scholar
• EORTC.org [Internet]. Brussels: European Organisation for Research and Treatment of Cancer; [cited 2019 Nov 06]. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf.
   Google Scholar
• Delforge M, Minuk L, Eisenmann J, et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015;100(6):826–833.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delforge M, Hájek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98(5):784–788.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Hajek R, et al. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leuk Lymphoma. 2014;55(7):1489–1497.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34(32):3921–3930.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Moreau P, Dimopoulos MA, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9(3):23.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27(10):1959–1969.
   PubMed Web of Science ®Google Scholar
• Abonour R, Wagner L, Durie BGM, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Ann Hematol. 2018;97(12):2425–2436.
   PubMed Web of Science ®Google Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57–73.
   PubMed Web of Science ®Google Scholar
• Nielsen LK, Stege C, Lissenberg-Witte B, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica. 2019 Sep 12. DOI:10.3324/haematol.2019.222299 [Epub ahead of print].
   Google Scholar
• Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018;2(13):1608–1615.
   PubMed Web of Science ®Google Scholar
• Cherniawsky H, Kukreti V, Reece D, et al. The impact of lenalidomide maintenance on second line chemotherapy in transplant eligible patients with multiple myeloma in the Canadian setting. Clin Lymphoma Myeloma Leuk. 2019;19(10):e250.
   Web of Science ®Google Scholar
• Hari P, Ung B, Abouzaid S, et al. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs. Future Oncol. 2019;15(35):4045–4056.
   PubMed Web of Science ®Google Scholar
• Reece D, Kouroukis CT, Leblanc R, et al. Practical approaches to the use of lenalidomide in multiple myeloma: a Canadian consensus. Adv Hematol. 2012;2012:621958.
   PubMedGoogle Scholar